Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BEAM

BEAM - Beam Therapeutics Inc Stock Price, Fair Value and News

23.17USD-0.86 (-3.58%)Market Closed

Market Summary

BEAM
USD23.17-0.86
Market Closed
-3.58%

BEAM Alerts

  • Losses in recent quarter

BEAM Stock Price

View Fullscreen

BEAM RSI Chart

BEAM Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-14.15

Price/Sales (Trailing)

5.05

EV/EBITDA

-32.37

Price/Free Cashflow

-11.27

BEAM Price/Sales (Trailing)

BEAM Profitability

EBT Margin

-18.78%

Return on Equity

-14.75%

Return on Assets

-9.91%

Free Cashflow Yield

-8.88%

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

377.7M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

1.7K%

BEAM Earnings

Earnings (TTM)

-134.7M

Earnings Growth (Yr)

-2.29%

Earnings Growth (Qtr)

-169.1%

Breaking Down BEAM Revenue

Last 7 days

-6.8%

Last 30 days

-5.9%

Last 90 days

-33.6%

Trailing 12 Months

-31.2%

How does BEAM drawdown profile look like?

BEAM Financial Health

Current Ratio

5.99

BEAM Investor Care

Shares Dilution (1Y)

8.00%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202376.7M80.2M81.6M377.7M
202254.1M56.4M58.7M60.9M
202113.0M25.9M38.9M51.8M
202000024.0K
20190000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Beam Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 26, 2024
burrell terry-ann
acquired
-
-
12,500
chief financial officer
Apr 02, 2024
simon amy
sold
-504,851
30.5415
-16,530
chief medical officer
Apr 01, 2024
evans john m.
sold
-581,617
32.13
-18,102
ceo
Apr 01, 2024
burrell terry-ann
sold
-174,926
32.12
-5,446
chief financial officer
Apr 01, 2024
bellon christine
sold
-109,240
32.12
-3,401
chief legal officer
Apr 01, 2024
ciaramella giuseppe
sold
-145,632
32.12
-4,534
president
Apr 01, 2024
simon amy
sold
-229,954
32.13
-7,157
chief medical officer
Mar 31, 2024
burrell terry-ann
acquired
-
-
27,500
chief financial officer
Mar 31, 2024
bellon christine
acquired
-
-
27,500
chief legal officer
Mar 31, 2024
simon amy
acquired
-
-
27,500
chief medical officer

1–10 of 50

Which funds bought or sold BEAM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
1,019
1,019
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
226,000
1,698,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
9.89
37,309,700
149,068,000
0.68%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
64.67
262,964
525,964
0.07%
May 20, 2024
Virtu Financial LLC
new
-
875,000
875,000
0.07%
May 16, 2024
Virtus Investment Advisers, Inc.
sold off
-100
-82,994
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-50.63
-3,797,030
5,676,830
-%
May 16, 2024
COMERICA BANK
reduced
-11.1
2,094
28,575
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.87
350,081
2,306,660
-%
May 16, 2024
Ancora Advisors LLC
unchanged
-
291
1,652
-%

1–10 of 42

Are Funds Buying or Selling BEAM?

Are funds buying BEAM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BEAM
No. of Funds

Unveiling Beam Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
arch venture fund ix, l.p.
6.7%
5,443,039
SC 13G/A
Feb 13, 2024
vanguard group inc
8.79%
7,164,843
SC 13G/A
Feb 12, 2024
farallon capital partners, l.p.
0.7%
542,347
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 06, 2024
temasek holdings (private) ltd
3.8%
3,076,117
SC 13G/A
Jan 29, 2024
ark investment management llc
11.53%
9,393,889
SC 13G/A
Jan 25, 2024
blackrock inc.
8.2%
6,662,043
SC 13G/A
Jan 24, 2024
state street corp
5.66%
4,616,358
SC 13G
Sep 22, 2023
farallon capital partners, l.p.
0.4%
306,547
SC 13G
Mar 17, 2023
temasek holdings (private) ltd
5.0%
3,644,573
SC 13G

Recent SEC filings of Beam Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
Apr 29, 2024
4
Insider Trading

Peers (Alternatives to Beam Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-3.00% -55.11%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
6.00% 71.52%
-4.86
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.7M
2.1M
15.15% 225.71%
-0.85
7.61
-13.45% 69.54%

Beam Therapeutics Inc News

Latest updates
StockTitan17 hours ago

Beam Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-316,192,00017,193,00020,116,00024,208,00020,037,00015,799,00016,652,0008,432,0006,325,5004,219,0002,112,5006,0006,0006,000162,800319,600476,400633,200790,000498,000
Operating Expenses-39.2%111,542,000183,334,000125,460,000122,264,000123,136,000109,022,000107,102,00098,618,00084,657,000114,553,00070,397,00058,980,000200,379,00040,805,00037,327,00026,291,00028,361,00026,377,00018,030,00017,657,00013,108,000
  S&GA Expenses-38.2%26,724,00043,257,00025,410,00024,656,00023,490,00022,681,00021,815,00024,062,00019,247,00017,772,00015,774,00013,403,00010,273,0008,354,0007,502,0006,937,0006,812,0006,160,0005,487,0004,977,0003,929,000
  R&D Expenses-39.4%84,818,000140,077,000100,050,00097,608,00099,646,00086,341,00085,287,00074,556,00065,410,00096,781,00054,623,00045,577,000190,106,00032,451,00029,825,00019,354,00021,549,00020,217,00012,543,00012,680,0009,179,000
EBITDA Margin1.5%-0.13-0.13-2.96-3.03-3.19-4.03-6.09-6.37-6.67-6.99-4.83-7.27---------
Interest Expenses-30.0%14,00020,00028,00050,00062,00076,00086,000101,000113,000124,000136,000148,000159,000139,000140,000------
Income Taxes-100.0%-1,366,000---1,010,0002,410,000-----159,000-422,000140,000148,000134,000----
Earnings Before Taxes-100.0%-144,163,000-96,088,000---37,349,000-81,665,000----28,118,000----------
EBT Margin0%-0.19-0.19-3.19-3.25-3.39-4.27-6.32-6.57-6.85-7.15-5.00-7.50---------
Net Income-169.1%-98,669,000142,797,000-96,088,000-82,776,000-96,460,000-38,349,000-109,575,000-71,950,000-69,214,000-64,707,000-28,118,000-76,253,000-201,560,000-95,464,000-34,452,000-34,218,000-30,458,000-27,850,000-19,005,000-17,861,000-13,610,000
Net Income Margin-1.7%-0.36-0.35-3.85-4.08-4.12-4.75-5.38-4.15-4.40-7.15-10.32-15.72---------
Free Cashflow-177.7%-102,185,000131,484,000-97,732,000-100,847,000-115,832,000-77,452,000-86,283,000-73,920,000211,231,000-11,539,000-2,773,000-48,711,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-6.8%1,3601,4601,2911,3541,3321,3421,3501,4181,4531,4741,157893693452278300323156
  Current Assets-7.4%1,1221,2111,0401,0951,0831,0931,1091,1801,2391,27394167851530820923526095.00
    Cash Equivalents-34.0%28843616922625024615726629756061221297.0017713812512651.00
  Net PPE-3.2%12112512812812211611110694.0084.0072.0064.0052.0039.0029.0026.0025.0024.00
Liabilities-6.7%44647851254257160863661862464830334527120678.0069.0061.0055.00
  Current Liabilities-8.9%18720622021022022423921221921310112910210247.0039.0031.0029.00
Shareholder's Equity-6.9%913981779812762733714800829827854549422246200231261-
  Retained Earnings-9.3%-1,300-1,189-1,300-1,200-1,200-1,057-1,000-909-837-768-703-675-599-397-302-267-233-203
  Additional Paid-In Capital1.5%2,2022,1702,1132,0491,9151,7931,7371,7131,6691,5941,5571,2231,0216435024984952.00
Shares Outstanding0.8%82.0082.0079.0078.0072.0071.0070.0069.0069.0064.0066.0061.00------
Float----2,110---2,460---6,450---982--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-173.8%-99.75135-89.78-84.67-109-69.19-74.50-52.282182.003.00-32.53-38.58-24.30-21.21-22.84-27.39-17.80-16.99-11.35-25.86
  Share Based Compensation29.5%29.0023.0026.0026.0024.0022.0022.0022.0018.0016.0013.0010.005.007.003.003.003.002.002.002.001.00
Cashflow From Investing-154.5%-53.4698.00-10.23-41.4825.00113-36.17-1.26-537-77.5076.00-13.14-279-81.4335.0023.00-76.7917.0014.00-95.08-2.35
Cashflow From Financing-91.4%3.0034.0037.0010898.0032.002.0022.0056.0022.003211602531300.00-0.781931.003.00-0.0238.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BEAM Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
License and collaboration revenue$ 7,410$ 24,208
Revenue, Product and Service [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:  
Research and development$ 84,818$ 99,646
General and administrative26,72423,490
Total operating expenses111,542123,136
Loss from operations(104,132)(98,928)
Other income (expense):  
Change in fair value of derivative liabilities(2,900)5,600
Change in fair value of non-controlling equity investments(3,353)(12,797)
Change in fair value of contingent consideration liabilities(133)(296)
Interest and other income (expense), net11,8499,961
Total other income (expense)5,4632,468
Net loss(98,669)(96,460)
Unrealized gain (loss) on marketable securities(1,525)1,665
Comprehensive loss$ (100,194)$ (94,795)
Net loss per common share, basic$ (1.21)$ (1.33)
Net loss per common share, diluted$ (1.21)$ (1.33)
Weighted - average common shares outstanding, basic81,698,63372,273,829
Weighted - average common shares outstanding, diluted81,698,63372,273,829

BEAM Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 287,848$ 435,895
Marketable securities806,706753,981
Prepaid expenses and other current assets27,15621,167
Total current assets1,121,7101,211,043
Property and equipment, net120,922124,960
Restricted cash6,4528,719
Operating lease right-of-use assets109,023112,846
Other assets1,6892,146
Total assets1,359,7961,459,714
Current liabilities:  
Accounts payable2,7901,617
Accrued expenses and other current liabilities86,437111,664
Derivative liabilities13,70010,800
Current portion of deferred revenue72,11168,706
Current portion of lease liability12,18112,778
Total current liabilities187,219205,565
Long-term lease liability155,939159,911
Contingent consideration liabilities2,8562,723
Long-term portion of deferred revenue99,573109,888
Other liabilities719298
Total liabilities446,306478,385
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:  
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 82,280,827 and 81,632,496 issued and outstanding at March 31, 2024 and December 31, 2024, respectively823816
Additional paid-in capital2,202,1462,169,798
Accumulated other comprehensive (loss) income(921)604
Accumulated deficit(1,288,558)(1,189,889)
Total stockholders' equity913,490981,329
Total liabilities and stockholders' equity$ 1,359,796$ 1,459,714
BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://beamtx.com
 INDUSTRYBiotechnology
 EMPLOYEES532

Beam Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Beam Therapeutics Inc? What does BEAM stand for in stocks?

BEAM is the stock ticker symbol of Beam Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Beam Therapeutics Inc (BEAM)?

As of Tue Jun 18 2024, market cap of Beam Therapeutics Inc is 1.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart for subscribers.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart for subscribers. The fair value of Beam Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Beam Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BEAM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Beam Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BEAM is over valued or under valued. Whether Beam Therapeutics Inc is cheap or expensive depends on the assumptions which impact Beam Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BEAM.

What is Beam Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, BEAM's PE ratio (Price to Earnings) is -14.15 and Price to Sales (PS) ratio is 5.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BEAM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Beam Therapeutics Inc's stock?

In the past 10 years, Beam Therapeutics Inc has provided -0.127 (multiply by 100 for percentage) rate of return.